Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Fore Biotherapeutics
AddedFeb 15, 2024
UpdatedJun 18, 2026
Fore Biotherapeutics

Fore Biotherapeutics

Pioneering precision oncology firm, developing innovative, genomics-guided cancer therapies.

HQ
Philadelphia, PA, US
Founded
2011
Overview
Compare
Fundraising
Employees
Website

Fore Biotherapeutics, founded with a mission to revolutionize cancer treatment, is a precision oncology company focused on developing innovative therapies guided by proprietary functional genomics. The company's vision is to compassionately contribute to solving cancer through science and innovation. Fore Biotherapeutics offers a range of genomics-guided cancer therapies, with a market focus on precision oncology, aiming to provide targeted treatments for various cancer types.

Notable figures affiliated with Fore Biotherapeutics include leaders in oncology and genomics research, as well as prominent investors from the biotech sector. The company has achieved significant milestones, including the development of its flagship program, Plixorafenib. Fore Biotherapeutics' impact is marked by its contribution to personalized cancer treatment, offering hope to patients through advanced, targeted therapeutic options.

Fore Biotherapeutics - Similar Companies

D2G Oncology logo

D2G Oncology

d2g-oncology.com

Function Oncology logo

Function Oncology

Foundation Medicine logo

Foundation Medicine

Palm Therapeutics logo

Palm Therapeutics

OncoPrecision logo

OncoPrecision

oncoprecision.bio

Oncolix logo

Oncolix

Fresh Wind Biotechnologies USA logo

Fresh Wind Biotechnologies USA

Synnovation Therapeutics logo

Synnovation Therapeutics

synnovationtx.com

Personalis logo

Personalis

personalis.com

Alphina Therapeutics logo

Alphina Therapeutics

Geneos Therapeutics logo

Geneos Therapeutics

geneostx.com

Encoded Therapeutics logo

Encoded Therapeutics

Cartography Biosciences logo

Cartography Biosciences

cartography.bio

EcoGenome logo

EcoGenome

ecogenomellc.com

Accelerated Pharma logo

Accelerated Pharma

Fore Biotherapeutics - Quick Facts

Who are Fore Biotherapeutics' competitors?

Companies similar to Fore Biotherapeutics include D2G Oncology, Function Oncology, Foundation Medicine and Palm Therapeutics.

When was Fore Biotherapeutics founded?

Fore Biotherapeutics was founded in 2011.

Where is Fore Biotherapeutics' headquarters located?

Fore Biotherapeutics' headquarters is located in Philadelphia, PA, US.

When was Fore Biotherapeutics' last funding round?

Fore Biotherapeutics' most recent funding round was for $75M (USD) in August 2023.

How much has Fore Biotherapeutics raised to-date?

As of Aug 23, 2023, Fore Biotherapeutics has raised a total of $166.5M (USD).

How many employees does Fore Biotherapeutics have?

Fore Biotherapeutics has 45 employees as of Feb 4, 2024.

Fore Biotherapeutics - Classification

Ownership
  • Venture Capital
Technology
  • Genomics
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Cancer Therapies
Tags
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software